Egrifta (Tesamorelin Acetate) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising incidence of hiv-associated lipodystrophy, long-term antiretroviral therapy side effects, clinical validation of ghrh analogs, increasing awareness of visceral fat risks, unmet need for targeted abdominal fat reduction.

The growth in the forecast period can be attributed to growth in personalized hiv care, pipeline expansion for peptide therapeutics, increasing diagnosis of metabolic complications, supportive reimbursement for specialty drugs, focus on long-term quality of life in hiv patients. Major trends in the forecast period include long-acting peptide therapies, personalized lipodystrophy treatment, expansion of metabolic indications, patient-centric injectable therapies, specialty biologic drug adoption.

The rising prevalence of human immunodeficiency virus (HIV) cases is expected to significantly drive the growth of the egrifta (tesamorelin acetate) market. HIV infections gradually weaken the immune system in affected individuals. The increase in HIV cases is partly attributed to insufficient awareness and education about preventive measures, such as condom use and regular testing, especially in high-risk populations. Egrifta stimulates growth hormone release, which helps reduce excess visceral fat, improve body composition, and enhance overall health and quality of life for individuals living with HIV. For example, in May 2024, the Minnesota Department of Health, a US-based state health agency, reported 324 new HIV diagnoses in 2023, reflecting a 24% increase from 2022. Therefore, the rising prevalence of HIV is expected to propel growth in the Egrifta market.

A key trend in the egrifta market is the development of advanced synthetic peptide drugs aimed at improving the treatment of HIV-related lipodystrophy. Synthetic peptide drugs are artificially designed compounds intended to deliver targeted therapeutic effects by mimicking or enhancing the action of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced the resumption of EGRIFTA SV production following a voluntary shutdown at its contract manufacturer’s facility due to FDA inspection observations. A newly manufactured batch has completed quality control and will be released once the FDA approves a prior approval supplement, with two additional batches currently in production. The company is managing inventory to meet patient demand through mid-January 2025 and is collaborating with the FDA to prevent a potential shortage in 2025. EGRIFTA SV is distributed exclusively in the United States.

In January 2023, the World Orphan Drug Alliance (WODA), a Slovenia-based alliance of commercial distributors focused on providing access to treatments for rare diseases, announced a major agreement with Theratechnologies for the distribution of EGRIFTA SV. This medication helps reduce excess visceral abdominal fat in adults living with HIV and lipodystrophy. The partnership is intended to improve the availability and accessibility of EGRIFTA SV for patients managing these conditions. Theratechnologies Inc., based in Canada, is the manufacturer of egrifta (tesamorelin acetate).

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the egrifta (tesamorelin acetate) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the egrifta market by increasing costs for imported peptide raw materials, pharmaceutical intermediates, and biologics manufacturing equipment. These higher input costs have affected pricing strategies and supply chain stability, particularly in North America and Europe where cross-border sourcing is common. Hospital and retail pharmacy channels experience margin pressure due to elevated procurement expenses. At the same time, tariffs are encouraging local manufacturing, supply chain diversification, and greater investment in domestic biologics production capabilities, supporting long-term market resilience.

The egrifta (tesamorelin acetate) market research report is one of a series of new reports that provides egrifta (tesamorelin acetate) market statistics, including egrifta (tesamorelin acetate) industry global market size, regional shares, competitors with a egrifta (tesamorelin acetate) market share, detailed egrifta (tesamorelin acetate) market segments, market trends and opportunities, and any further data you may need to thrive in the egrifta (tesamorelin acetate) industry. This egrifta (tesamorelin acetate) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Egrifta (tesamorelin acetate) is a synthetic peptide that helps reduce excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It functions as a growth hormone-releasing hormone (GHRH) analog to specifically target and decrease visceral fat. By promoting fat breakdown, it enhances fat distribution and lowers health risks linked to abdominal fat.

The primary clinical indications for egrifta (tesamorelin acetate) include HIV-associated lipodystrophy, growth hormone deficiency, abdominal obesity, and metabolic syndrome. HIV-associated lipodystrophy is a condition in people with HIV characterized by abnormal fat distribution, including fat loss in the limbs and excess fat accumulation in the abdomen. The medication is distributed through hospital and retail pharmacies, online pharmacies, and other channels, and is used by hospitals, specialized clinics, and home care providers.

The egrifta (tesamorelin acetate) market consists of sales of tesamorelin acetate injections and tesamorelin acetate vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.